Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection (REVERSE2)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05948592 |
Recruitment Status :
Recruiting
First Posted : July 17, 2023
Last Update Posted : April 11, 2024
|
Tracking Information | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | June 15, 2023 | ||||||||||||||||||||||||||||||
First Posted Date ICMJE | July 17, 2023 | ||||||||||||||||||||||||||||||
Last Update Posted Date | April 11, 2024 | ||||||||||||||||||||||||||||||
Actual Study Start Date ICMJE | November 8, 2023 | ||||||||||||||||||||||||||||||
Estimated Primary Completion Date | April 30, 2024 (Final data collection date for primary outcome measure) | ||||||||||||||||||||||||||||||
Current Primary Outcome Measures ICMJE |
|
||||||||||||||||||||||||||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||||||||||||||||||||||||||
Change History | |||||||||||||||||||||||||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||||||||||||||||||||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||||||||||||||||||||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||||||||||||||||||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||||||||||||||||||||||||
Descriptive Information | |||||||||||||||||||||||||||||||
Brief Title ICMJE | Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection | ||||||||||||||||||||||||||||||
Official Title ICMJE | A Phase 2 CT to Evaluate the Safety and Efficacy of Topical Administration of Bacteriophage Therapy TP-102 in Patients With DFI | ||||||||||||||||||||||||||||||
Brief Summary | TP-102 is a novel bacteriophage cocktail comprised of 5 (five) lytic bacteriophages against Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii. TP-102 is being developed for topical treatment of patients with wound infections including chronic ulcers; applied every other day (three times weekly (TIW)). | ||||||||||||||||||||||||||||||
Detailed Description | This is a Phase 2b, double-blinded, randomised, placebo-controlled multicenter study to determine the safety and efficacy of TP-102, in patients with diabetic foot infection. Eighty (80) patients with an infected diabetic foot ulcer and with at least one target bacterial strain (Pseudomonas aeruginosa, Staphylococcus aureus or Acinetobacter baumannii) susceptible to TP-102. Patients will be randomised to receive TP-102 or placebo, in a 1:1 ratio. Patients will be treated with 1 (one) mL of IP/ Placebo solution applied topically per cm3 of target ulcer. Patients will be treated with a total of 12 treatments in 28 days (+3 days) with at least one day of interval in between the days of treatment (no consecutive days of treatment are allowed) and a maximum of 3 (three) days without treatment. The titre of each bacteriophage in TP-102 is 1x109 (>1x108 and < 1x1010) plaque forming units per milliliter (PFU/mL). Assessments for efficacy and safety will include concomitant medications and AEs, local tolerability, clinical laboratory tests, vital signs, physical examination, wound biopsy/swab to determine the presence, speciation and TP-102 sensitivity of bacteria and target ulcer assessment. |
||||||||||||||||||||||||||||||
Study Type ICMJE | Interventional | ||||||||||||||||||||||||||||||
Study Phase ICMJE | Phase 2 | ||||||||||||||||||||||||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
||||||||||||||||||||||||||||||
Condition ICMJE | Diabetic Foot Infection | ||||||||||||||||||||||||||||||
Intervention ICMJE |
|
||||||||||||||||||||||||||||||
Study Arms ICMJE |
|
||||||||||||||||||||||||||||||
Publications * | Not Provided | ||||||||||||||||||||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||||||||||||||||||
Recruitment Information | |||||||||||||||||||||||||||||||
Recruitment Status ICMJE | Recruiting | ||||||||||||||||||||||||||||||
Estimated Enrollment ICMJE |
80 | ||||||||||||||||||||||||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||||||||||||||||||||||||
Estimated Study Completion Date ICMJE | July 31, 2024 | ||||||||||||||||||||||||||||||
Estimated Primary Completion Date | April 30, 2024 (Final data collection date for primary outcome measure) | ||||||||||||||||||||||||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||||||||||||||||||||||||
Sex/Gender ICMJE |
|
||||||||||||||||||||||||||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||||||||||||||||||||||||||
Accepts Healthy Volunteers ICMJE | No | ||||||||||||||||||||||||||||||
Contacts ICMJE |
|
||||||||||||||||||||||||||||||
Listed Location Countries ICMJE | India, United States | ||||||||||||||||||||||||||||||
Removed Location Countries | |||||||||||||||||||||||||||||||
Administrative Information | |||||||||||||||||||||||||||||||
NCT Number ICMJE | NCT05948592 | ||||||||||||||||||||||||||||||
Other Study ID Numbers ICMJE | TP-102_102 | ||||||||||||||||||||||||||||||
Has Data Monitoring Committee | Yes | ||||||||||||||||||||||||||||||
U.S. FDA-regulated Product |
|
||||||||||||||||||||||||||||||
IPD Sharing Statement ICMJE |
|
||||||||||||||||||||||||||||||
Current Responsible Party | Technophage, SA | ||||||||||||||||||||||||||||||
Original Responsible Party | Same as current | ||||||||||||||||||||||||||||||
Current Study Sponsor ICMJE | Technophage, SA | ||||||||||||||||||||||||||||||
Original Study Sponsor ICMJE | Same as current | ||||||||||||||||||||||||||||||
Collaborators ICMJE | VectorB2B | ||||||||||||||||||||||||||||||
Investigators ICMJE |
|
||||||||||||||||||||||||||||||
PRS Account | Technophage, SA | ||||||||||||||||||||||||||||||
Verification Date | April 2024 | ||||||||||||||||||||||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |